Scienture Holdings, Inc. (SCNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scienture Holdings, Inc. (SCNX) has a cash flow conversion efficiency ratio of -0.049x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.13 Million) by net assets ($64.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SCNX company net worth for the company's overall valuation and market capitalisation.
Scienture Holdings, Inc. - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Scienture Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Scienture Holdings, Inc. (SCNX) share price today for real-time trading data and today's change.
Scienture Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scienture Holdings, Inc. ranked by their cash flow conversion efficiency. Review Scienture Holdings, Inc. free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Conquest Resources Ltd
V:CQR
|
-0.111x |
|
Dongil Technology Ltd
KQ:032960
|
0.011x |
|
CYL Corporation Bhd
KLSE:7157
|
0.081x |
|
Birlik Mensucat Ticaret ve Sanayi Isletmesi AS
IS:BRMEN
|
25.838x |
|
Baijiayun Group Ltd
NASDAQ:RTC
|
-1.214x |
|
Equity Development Investment
JK:GSMF
|
-0.023x |
|
Innovative Eyewear Inc.
NASDAQ:LUCY
|
-0.270x |
|
Golden Deeps Ltd
AU:GED
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Scienture Holdings, Inc. (2006–2025)
The table below shows the annual cash flow conversion efficiency of Scienture Holdings, Inc. from 2006 to 2025. Also see Scienture Holdings, Inc. asset portfolio for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.12 Million | $-13.38 Million | -0.191x | -5.77% |
| 2024-12-31 | $79.07 Million | $-14.27 Million | -0.180x | +95.60% |
| 2023-12-31 | $542.35K | $-2.23 Million | -4.103x | +10.09% |
| 2022-12-31 | $342.87K | $-1.56 Million | -4.563x | -570.44% |
| 2021-12-31 | $3.77 Million | $-2.57 Million | -0.681x | -166.73% |
| 2020-12-31 | $8.68 Million | $-2.21 Million | -0.255x | -845.21% |
| 2019-12-31 | $4.14 Million | $141.78K | 0.034x | -89.42% |
| 2018-12-31 | $844.67K | $273.39K | 0.324x | +158.81% |
| 2017-12-31 | $-311.93K | $171.67K | -0.550x | -148.11% |
| 2016-12-31 | $-1.15 Million | $-1.31 Million | 1.144x | +115.48% |
| 2015-12-31 | $267.02K | $-1.97 Million | -7.392x | -364.14% |
| 2014-12-31 | $668.44K | $-1.06 Million | -1.593x | +75.32% |
| 2013-12-31 | $130.87K | $-844.58K | -6.454x | +30.83% |
| 2012-12-31 | $17.48K | $-163.12K | -9.330x | -112.00% |
| 2011-12-31 | $-2.34K | $-181.89K | 77.764x | +13256078.98% |
| 2008-12-31 | $-48.01 Million | $-28.16K | 0.001x | -99.93% |
| 2007-12-31 | $-18.51K | $-16.07K | 0.868x | +234.87% |
| 2006-12-31 | $9.67K | $-6.22K | -0.644x | -- |
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of… Read more